S&P 500   4,229.95 (-1.26%)
DOW   33,720.32 (-0.82%)
QQQ   322.92 (-1.93%)
AAPL   171.48 (-1.53%)
MSFT   286.10 (-1.40%)
META   168.03 (-3.80%)
GOOGL   117.28 (-2.40%)
AMZN   138.32 (-2.80%)
TSLA   890.06 (-2.04%)
NVDA   178.75 (-4.78%)
NIO   19.06 (-4.27%)
BABA   89.64 (-1.21%)
AMD   95.94 (-4.48%)
T   18.38 (-0.27%)
MU   60.44 (-4.03%)
CGC   3.76 (-1.31%)
F   15.87 (-1.73%)
GE   77.92 (-1.63%)
DIS   120.02 (-2.16%)
AMC   17.69 (-8.29%)
PYPL   96.66 (-3.20%)
PFE   49.10 (+1.07%)
NFLX   240.21 (-2.02%)
S&P 500   4,229.95 (-1.26%)
DOW   33,720.32 (-0.82%)
QQQ   322.92 (-1.93%)
AAPL   171.48 (-1.53%)
MSFT   286.10 (-1.40%)
META   168.03 (-3.80%)
GOOGL   117.28 (-2.40%)
AMZN   138.32 (-2.80%)
TSLA   890.06 (-2.04%)
NVDA   178.75 (-4.78%)
NIO   19.06 (-4.27%)
BABA   89.64 (-1.21%)
AMD   95.94 (-4.48%)
T   18.38 (-0.27%)
MU   60.44 (-4.03%)
CGC   3.76 (-1.31%)
F   15.87 (-1.73%)
GE   77.92 (-1.63%)
DIS   120.02 (-2.16%)
AMC   17.69 (-8.29%)
PYPL   96.66 (-3.20%)
PFE   49.10 (+1.07%)
NFLX   240.21 (-2.02%)
S&P 500   4,229.95 (-1.26%)
DOW   33,720.32 (-0.82%)
QQQ   322.92 (-1.93%)
AAPL   171.48 (-1.53%)
MSFT   286.10 (-1.40%)
META   168.03 (-3.80%)
GOOGL   117.28 (-2.40%)
AMZN   138.32 (-2.80%)
TSLA   890.06 (-2.04%)
NVDA   178.75 (-4.78%)
NIO   19.06 (-4.27%)
BABA   89.64 (-1.21%)
AMD   95.94 (-4.48%)
T   18.38 (-0.27%)
MU   60.44 (-4.03%)
CGC   3.76 (-1.31%)
F   15.87 (-1.73%)
GE   77.92 (-1.63%)
DIS   120.02 (-2.16%)
AMC   17.69 (-8.29%)
PYPL   96.66 (-3.20%)
PFE   49.10 (+1.07%)
NFLX   240.21 (-2.02%)
S&P 500   4,229.95 (-1.26%)
DOW   33,720.32 (-0.82%)
QQQ   322.92 (-1.93%)
AAPL   171.48 (-1.53%)
MSFT   286.10 (-1.40%)
META   168.03 (-3.80%)
GOOGL   117.28 (-2.40%)
AMZN   138.32 (-2.80%)
TSLA   890.06 (-2.04%)
NVDA   178.75 (-4.78%)
NIO   19.06 (-4.27%)
BABA   89.64 (-1.21%)
AMD   95.94 (-4.48%)
T   18.38 (-0.27%)
MU   60.44 (-4.03%)
CGC   3.76 (-1.31%)
F   15.87 (-1.73%)
GE   77.92 (-1.63%)
DIS   120.02 (-2.16%)
AMC   17.69 (-8.29%)
PYPL   96.66 (-3.20%)
PFE   49.10 (+1.07%)
NFLX   240.21 (-2.02%)
NASDAQ:HOLX

Hologic - HOLX Stock Forecast, Price & News

$71.29
-0.29 (-0.41%)
(As of 08/19/2022 03:47 PM ET)
Add
Compare
Today's Range
$71.11
$72.38
50-Day Range
$67.12
$73.47
52-Week Range
$66.58
$81.04
Volume
68,384 shs
Average Volume
1.47 million shs
Market Capitalization
$17.80 billion
P/E Ratio
12.02
Dividend Yield
N/A
Price Target
$76.71

Hologic MarketRank™ Forecast

Analyst Rating
Hold
2.30 Rating Score
Upside/​Downside
7.4% Upside
$76.71 Price Target
Short Interest
Bearish
3.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.94
Upright™ Environmental Score
News Sentiment
0.37mentions of Hologic in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-40.03%
From $5.82 to $3.49 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

878th out of 1,119 stocks

X - Ray Apparatus & Tubes Industry

2nd out of 4 stocks

HOLX stock logo

About Hologic (NASDAQ:HOLX) Stock

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Hologic Trading Down 0.3 %

Shares of NASDAQ:HOLX traded down $0.24 during trading on Friday, reaching $71.34. 39,679 shares of the company traded hands, compared to its average volume of 1,465,018. The firm has a market capitalization of $17.81 billion, a price-to-earnings ratio of 12.07, a P/E/G ratio of 0.81 and a beta of 1.05. Hologic has a 52-week low of $66.58 and a 52-week high of $81.04. The company has a current ratio of 3.91, a quick ratio of 3.32 and a debt-to-equity ratio of 0.57. The business's fifty day moving average is $70.57 and its 200-day moving average is $72.95.

Hologic (NASDAQ:HOLX - Get Rating) last released its quarterly earnings data on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.26. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $896.71 million. Hologic had a return on equity of 37.48% and a net margin of 28.93%. The business's quarterly revenue was down 14.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.33 earnings per share. As a group, analysts forecast that Hologic will post 5.82 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HOLX. Morgan Stanley lowered their price target on shares of Hologic from $72.00 to $70.00 and set an "equal weight" rating on the stock in a report on Thursday, July 28th. BTIG Research cut shares of Hologic from a "buy" rating to a "neutral" rating in a research report on Monday, July 18th. SVB Leerink upped their price objective on shares of Hologic to $85.00 and gave the stock an "outperform" rating in a research report on Tuesday, May 17th. UBS Group assumed coverage on shares of Hologic in a research report on Wednesday, July 20th. They issued a "neutral" rating and a $73.00 price objective on the stock. Finally, Citigroup decreased their price objective on shares of Hologic from $78.00 to $75.00 in a research report on Thursday, April 28th. Seven investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, Hologic currently has a consensus rating of "Hold" and an average price target of $76.71.

Receive HOLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hologic and its competitors with MarketBeat's FREE daily newsletter.

HOLX Stock News Headlines

Is the US Military Secretly Under Chinese Control?
Alarmingly, the answer may be "yes". Communist China now controls 80% of the lithium that powers most US military vehicles and equipment. The threat level is so high that the White House recently declared a state of emergency on lithium...
Brokerages Set Hologic, Inc. (NASDAQ:HOLX) PT at $75.50
The Coming Copper Bull Run
Copper prices have nearly doubled since last year -- driven by the explosive growth in electric vehicles and soaring demand for green-powered electricity. But copper demand far outpaces supply. Multinational investment banks are predicting a 50% to 100% rise in copper prices by 2025. And this "backdoor" play may be a move to consider.
Analyst Ratings for Hologic
See More Headlines
Receive HOLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hologic and its competitors with MarketBeat's FREE daily newsletter.

HOLX Company Calendar

Last Earnings
7/27/2022
Today
8/19/2022
Fiscal Year End
9/30/2022
Next Earnings (Estimated)
11/07/2022

Industry, Sector and Symbol

Industry
X - ray apparatus & tubes
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:HOLX
CUSIP
43644010
Employees
6,705
Year Founded
1985

Price Target and Rating

Average Stock Price Forecast
$76.71
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+7.6%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

Net Income
$1.87 billion
Pretax Margin
35.50%

Debt

Sales & Book Value

Annual Sales
$5.63 billion
Cash Flow
$10.14 per share
Book Value
$20.02 per share

Miscellaneous

Free Float
245,808,000
Market Cap
$17.80 billion
Optionable
Optionable
Beta
1.05

Social Links


Key Executives

  • Mr. Stephen P. MacMillanMr. Stephen P. MacMillan (Age 58)
    Chairman, CEO & Pres
    Comp: $4.51M
  • Ms. Karleen M. Oberton (Age 51)
    Chief Financial Officer
    Comp: $1.6M
  • Mr. John M. Griffin (Age 61)
    Gen. Counsel
    Comp: $1.56M
  • Mr. Sean S. DaughertyMr. Sean S. Daugherty (Age 46)
    Group Pres of Breast/Skeletal Health & GYN Surgical Solutions
    Comp: $1.32M
  • Mr. Kevin R. ThornalMr. Kevin R. Thornal (Age 48)
    Group Pres of Global Diagnostic Solutions
    Comp: $1.66M
  • Mr. Paul Malenchini
    Chief Information Officer
  • Ryan M. Simon
    VP of Investor Relations
  • Ms. Elisabeth A. Hellmann (Age 53)
    Sr. VP of Global HR & Corp. Communications
  • Mr. Jan VerstrekenMr. Jan Verstreken (Age 54)
    Group Pres of International
  • Ms. Monica Aguirre Berthelot
    VP & Chief of Staff













HOLX Stock - Frequently Asked Questions

Should I buy or sell Hologic stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HOLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HOLX, but not buy additional shares or sell existing shares.
View HOLX analyst ratings
or view top-rated stocks.

What is Hologic's stock price forecast for 2022?

10 brokerages have issued twelve-month target prices for Hologic's stock. Their HOLX share price forecasts range from $70.00 to $85.00. On average, they predict the company's stock price to reach $76.71 in the next year. This suggests a possible upside of 7.2% from the stock's current price.
View analysts price targets for HOLX
or view top-rated stocks among Wall Street analysts.

How have HOLX shares performed in 2022?

Hologic's stock was trading at $76.56 on January 1st, 2022. Since then, HOLX shares have decreased by 6.5% and is now trading at $71.58.
View the best growth stocks for 2022 here
.

When is Hologic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our HOLX earnings forecast
.

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) released its earnings results on Wednesday, July, 27th. The medical equipment provider reported $0.95 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.26. The medical equipment provider had revenue of $1 billion for the quarter, compared to analyst estimates of $896.71 million. Hologic had a trailing twelve-month return on equity of 37.48% and a net margin of 28.93%. Hologic's revenue was down 14.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.33 earnings per share.
Read the conference call transcript
.

What guidance has Hologic issued on next quarter's earnings?

Hologic updated its fourth quarter 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of $0.60-$0.65 for the period, compared to the consensus estimate of $0.61. The company issued revenue guidance of $840.00 million-$870.00 million, compared to the consensus revenue estimate of $869.95 million.

What is Steve MacMillan's approval rating as Hologic's CEO?

283 employees have rated Hologic Chief Executive Officer Steve MacMillan on Glassdoor.com. Steve MacMillan has an approval rating of 79% among the company's employees.

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), Walt Disney (DIS), PayPal (PYPL), Advanced Micro Devices (AMD), CVS Health (CVS), Pfizer (PFE) and Abbott Laboratories (ABT).

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Who are Hologic's major shareholders?

Hologic's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (13.89%), State Street Corp (4.60%), Macquarie Group Ltd. (2.52%), FMR LLC (2.19%), Parnassus Investments LLC (1.50%) and Victory Capital Management Inc. (1.44%). Insiders that own company stock include Benjamin Jordan Cohn, Christiana Stamoulis, Jan Verstreken, John M Griffin, Karleen Marie Oberton, Kevin R Thornal, Peter J Valenti III, Sally Crawford, Sean S Daugherty, Sean S Daugherty and Stephen P Macmillan.
View institutional ownership trends
.

How do I buy shares of Hologic?

Shares of HOLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $71.58.

How much money does Hologic make?

Hologic (NASDAQ:HOLX) has a market capitalization of $17.87 billion and generates $5.63 billion in revenue each year. The medical equipment provider earns $1.87 billion in net income (profit) each year or $5.93 on an earnings per share basis.

How many employees does Hologic have?

The company employs 6,705 workers across the globe.

Does Hologic have any subsidiaries?
The following companies are subsidiares of Hologic: Acessa Health, Acessa Health Inc., Beijing Hologic Technology Co. Ltd., Benassar Diagnostica-Equipamientos Medicos Unipessoal Lda., BioLucent, BioLucent LLC, Bioptics Inc., Biotheranostics Inc, Biotheranostics Inc., Bolder Surgical, Cynosure, Cytyc, Cytyc Corporation, Cytyc Prenatal Products Corp., Cytyc Surgical Products LLC, Diagenode Co. Ltd., Diagenode LLC, Diagenode SA, Diagenode SA., Diagenode SPA, Direct Radiography Corp., Emsor Sociedad de responsabilidad limitada, Faxitron Bioptics, Faxitron Bioptics LLC, Focal Therapeutics, Gen-Probe, Gen-Probe Incorporated, Gen-Probe Prodesse Inc., Gen-Probe Sales & Service Inc., Genewave SAS, Health Beacons Inc, Health Beacons Inc., Hologic (Australia & New Zealand) Pty Ltd., Hologic (MA) LLC, Hologic (Shanghai) Medical Supplies Co. Ltd., Hologic ASE LLC, Hologic Asia Limited, Hologic Asia Pacific Limited, Hologic Austria GmbH, Hologic BV, Hologic Bermuda Limited, Hologic Canada ULC, Hologic Caribbean (Barbados) SRL, Hologic Denmark ApS, Hologic Deutschland GmbH, Hologic Espana S.A., Hologic Finance Ltd., Hologic France SARL, Hologic GGO 2 LLC, Hologic GGO 3 LLP, Hologic GGO 4 LTD, Hologic Global Holding LTD, Hologic HUB LTD, Hologic Hitec-Imaging, Hologic Hitec-Imaging GmbH, Hologic Holdings Limited, Hologic IP LTD, Hologic Iberia S.L., Hologic India LLP, Hologic International Holdings B.V., Hologic Ireland Limited, Hologic Italia S.r.l., Hologic Japan KK, Hologic Latin America (Servicos Em Marketing E Negocios) Ltda., Hologic Ltd., Hologic Malaysia SDN. BHD., Hologic Medical Technologies (Beijing) Co. Ltd., Hologic Medicor GmbH, Hologic Medicor Suisse GmbH, Hologic Netherlands B.V., Hologic Nordic Holdings Oy, Hologic Singapore Pte. Ltd, Hologic Suisse SA, Hologic Surgical Products Costa Rica S.R.L., Hologic Sweden AB, Hologic Taiwan Ltd., Hologic UK Finance Ltd., Hologic US Finance Co LLC, Interlace Medical, Mobidiag Oy, Mobidiag Oy., Mobidiag UK Ltd., NXT-Dx SCRL, Navigation Three Limited, R2 Technology, Sentinelle Medical, Somatex (HK) Limited, Somatex Medical Technologies GmbH, Somatex Medical Technologies GmbH., Somatex USA Inc., SuperSonic Imagine (Shanghai) Medical Devices Co. Ltd., SuperSonic Imagine GmbH, SuperSonic Imagine HK Ltd, SuperSonic Imagine Ltd, SuperSonic Imagine SA, SuperSonic Imagine Srl, Suros Surgical Systems, Suros Surgical Systems Inc., TCT International, TCT International Co. Ltd., Third Wave Technologies, and Tridaho LLC.
Read More
When was Hologic founded?

Hologic was founded in 1985.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The official website for the company is www.hologic.com. The medical equipment provider can be reached via phone at (508) 263-2900, via email at michael.watts@hologic.com, or via fax at 781-890-8031.

This page (NASDAQ:HOLX) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.